Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY
Status
Hovedstatus
Detaljstatus 		Ikke i kraft info Patent opphørt Ikke betalt årsavgift
Patentnummer NO/EP2975042
Europeisk (EP) publiserings nummer EP2975042
EP levert
EP søknadsnummer 15181011.6
EP meddelt
Avdelt fra EP2585470
Prioritet 2010.06.23, KR 20100059686
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Hanmi Science Co., Ltd. (KR)
Oppfinner CHA, Mi Young (KR) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Patentkrav1. Forbindelse med formel (I) eller et farmasøytisk akseptabelt salt derav:hvori,W er O eller S;X er O, NH, S, SO eller SO2;Y er hydrogenatom, halogenatom, C1-6alkyl eller C1-6alkoksy;A og B er hver uavhengig hydrogenatom, halogenatom, eller di(C1-6alkyl)aminometyl; Z er aryl eller heteroaryl som har en eller flere substituenter valgt fra gruppen som består av: hydrogenatom, halogenatom, hydroksy, nitro, cyano, C1-6alkyl, C1-6alkoksy, C1-6alkylkarbonyl, C1-6alkoksykarbonyl, di(C1-6alkyl)aminoC2-6alkoksykarbonyl, amino, C1-6alkylamino, di(C1-6alkyl)amino, karbamoyl, C1-6alkylkarbamoyl,di(C1-6alkyl)karbamoyl, di(C1-6alkyl)aminoC2-6alkylkarbamoyl, sulfamoyl,C1-6alkylsulfamoyl, di(C1-6alkyl)sulfamoyl, di(C1-6alkyl)aminoC2-6alkylsulfamoyl,C1-6alkylsulfonyl, C1-6alkylsulfinyl, di(C1-6alkyl)fosfonyl, hydroksyC1-6alkyl, hydroksykarbonylC1-6alkyl, C1-6alkoksyC1-6alkyl, C1-6alkylsulfonylC1-6alkyl,C1-6alkylsulfinylC1-6alkyl, di(C1-6alkyl)fosfonylC1-6alkyl, hydroksyC2-6alkoksy, C1-6alkoksyC2-6alkoksy, aminoC1-6alkyl, C1-6alkylaminoC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl,di(C1-6alkyl)aminoacetyl, aminoC2-6alkoksy, C1-6alkylaminoC2-6alkoksy,di(C1-6alkyl)aminoC2-6alkoksy, hydroksyC2-6alkylamino, C1-6alkoksyC2-6alkylamino, aminoC2-6alkylamino, C1-6alkylaminoC2-6alkylamino, di(C1-6alkyl)aminoC2-6alkylamino, heteroaryl, heterosyklus, heterosyklisk oksy, heterosyklisk tio, heterosyklisk sulfinyl, heterosyklisk sulfonyl, heterosyklisk sulfamoyl, heterosyklisk C1-6alkyl, heterosyklisk C1-6alkoksy, heterosyklisk amino, heterosyklisk C1-6alkylamino, heterosyklisk aminoC1-6alkyl, heterosyklisk karbonyl, heterosyklisk C1-6alkylkarbonyl, heterosyklisk karbonylC1-6alkyl, heterosyklisk C1-6alkyltio, heterosyklisk C1-6alkylsulfinyl, heterosykliskC1-6alkylsulfonyl, heterosyklisk aminokarbonyl, heterosyklisk C1-6alkylaminokarbonyl, heterosyklisk aminokarbonylC1-6alkyl, heterosyklisk karboksamido, og heterosyklisk C1-6alkylkarboksamido;aryl refererer til en C6-12syklisk eller bisyklisk aromatisk ring;heteroarylene hver uavhengig refererer til en 5- til 12-leddet syklisk eller bisyklisk aromatisk heteroring som har ett eller flere N, O eller S; heterosyklylene hver uavhengig refererer til en mettet eller delvis umettet 3- til 12-leddet, syklisk eller bisyklisk heteroring med ett eller flere N, O, S, SO eller SO2, der et karbonatom som danner heterosyklusen eventuelt har en eller flere substituenter valgt fra gruppen som består av C1-6alkyl, hydroksy, hydroksyC1-6alkyl, hydroksykarbonyl, C1-6alkoksy, amino, C1-6alkylamino, di(C1-6alkyl)amino, di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)aminokarbonyl, heterosyklus, heterosyklisk C1-6alkyl, og heteroaryl, og der, gitt at heterosykluset eventuelt omfatter et nitrogenatom, har nitrogenatomet eventuelt en substituent valgt fra gruppen som består av hydrogenatom, C1-6alkyl, monohalogenoC1-6alkyl, dihalogenoC1-6alkyl, trihalogenoC1-6alkyl, C3-6sykloalkyl, hydroksyC2-6alkyl, C1-6alkoksyC2-6alkyl, C1-6alkylkarbonyl, hydroksyC1-6alkylkarbonyl, C1-6alkoksykarbonyl, karbamoyl, C1-6alkylkarbamoyl, di(C1-6alkyl)karbamoyl, sulfamoyl, C1-6alkylsulfamoyl, di(C1-6alkyl)sulfamoyl, C1-6alkylsulfonyl, aminoC2-6alkyl,C1-6alkylaminoC2-6alkyl, di(C1-6alkyl)aminoC2-6alkyl, di(C1-6alkyl)aminoC1-6alkylkarbonyl, heterosyklus, heterosyklisk oksy, heterosyklisk tio, heterosyklisk sulfinyl, heterosyklisk sulfonyl, heterosyklisk C1-6alkyl, heterosyklisk karbonyl, heterosyklisk C1-6alkylkarbonyl, heterosyklisk C1-6alkylsulfinyl, og heterosyklisk C1-6alkylsulfonyl (hvori, når nitrogenatomet danner tertiært amin, et det eventuelt av en N-oksidform); og eventuelt er C1-6alkylet delvis umettet eller har en C3-6sykloalkylrest, og et karbonatom i heterosyklusen foreligger i en karbonylform.2. Forbindelsen ifølge krav 1, hvori Z er valgt fra gruppen som består av formlene Z1 til Z203:3. Forbindelsen ifølge krav 1, hvori forbindelsen med formel (I) er valgt fra gruppen som består av: N-(3-(2-(2-metoksy-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-tert-butyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2-fluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2,2,2-trifluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2-metoksy-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2-hydroksy-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-hydroksy-4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(3,4,5-trimetyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(5-metyl-2,5-diaza-bisyklo[2.2.1]hept-2-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(1-metyl-2-okso-2,3,4,5-tetrahydro-1H-benzo[b]azepin-7-ylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(2-metoksy-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(2-metoksy-4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;Dietyl(4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)fenyl)fosfonat; N-(3-(2-(4-[1,4']bipiperidinyl-1'-yl-3-fluor-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-((2-((3-klor-4-(4-metylpiperazin-1-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-(1-metylpiperidin-4-ylamino)-3-klorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(2-fluor-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(3-metyl-4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-2-metyl-N(1-metylpiperidin-4-yl)benzamid;N-(4-metyl-3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(4-fluor-3-(2-(4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(4-metoksy-3-(2-(4-(4-metylpiperazin-1-yl)-fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(5-(4-metylpiperazin-1-yl)pyridin-2-ylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;4-metyl-piperazin-1-karboksylsyre (4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-d]pyrimidin-2-ylamino)-fenyl)-amid;N-(4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-2-fluorfenyl)-4-metylpiperazin-1-karboksamid;N-(3-(2-(4-(4-etylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-isopropyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2,2-difluor-etyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-imidazol-1-yl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; N-(3-(2-(4-(piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(4-(4-(2-dimetylamino-acetyl)-piperazin-1-yl)-3-fluor-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-(piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-(metylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-acetylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-(morfolin-4-karbonyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1,4-dimetyl-3-okso-piperazin-2-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-morfolinofenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-((2-((4-((2-(dimetylamino)etyl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-((2-(4-metylpiperazin-1-yl)etyl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-tiomorfolinofenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(1-okso-1λ4-tiomorfolin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;(S)-N-(3-(2-(4-(3-(dimetylamino)pyrrolidin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-pyrrolidin-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-[1,4']bipiperidinyl-1'-yl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;1-(4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-d]pyrimidin-2-ylamino)-fenyl)-piperidin-4-karboksylsyredimetylamid;N-(3-(2-(4-(dimetylamino)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(4-(2-hydroksy-etyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-dimetylamino-etyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-fluorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-hydroksyfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-((2-((4-acetylfenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(1,4,5,6-tetrahydropyrimidin-2-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)okso)fenyl)akrylamid;N-(3-(2-(3-fluor-2-metoksy-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(4-etylpiperazin-1-yl)piperidin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(3R-imidazol-1-yl-pyrrolidin-1-yl)-fenylamino]-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(3-imidazol-1-yl-pyrrolidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-imidazol-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-dimetylamino-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; N-(3-(2-(4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(4-pyrrolidin-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-1-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-(4-morfolin-4-yl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-hydroksypiperidin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-((2-((4-(4-(hydroksymetyl)piperidin-1-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(4-(2-hydroksyetyl)piperidin-1-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-(4-(etylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-((4-etylpiperazin-1-yl)metyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-dietylaminometyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-morfolin-4-yl-piperidin-1-ylmetyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;(E)-N-(3-((2-((4-(3-(dimetylamino)prop-1-en-1-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-((1-metylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-dietylaminometyl-2-metoksy-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-((4-metylpiperazin-1-yl)metyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(3-fluor-4-(4-metyl-piperazin-1-ylmetyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(piperidin-1-ylmetyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-azetidin-1-ylmetyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; N-(3-(2-(4-pyrrolidin-1-ylmetyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(morfolinometyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-((2-((4-((3-(dimetylamino)pyrrolidin-1-yl)metyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-((4-hydroksypiperidin-1-yl)metyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-((4-(dimetylamino)piperidin-1-yl)metyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;Dimetyl(4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)benzylfosfonat; N-(3-(2-(4-((dimetylamino)metyl)-3-fluorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-((3-(dimetylamino)pyrrolidin-1-yl)metyl)3-fluorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-((4-(dimetylamino)piperidin-1-yl)metyl)3-fluorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-((1-metylpiperidin-4-ylamino)metyl)-3-fluorfenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-dimetylaminometyl-2-metyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-((4-(syklopropylmetyl)piperazin-1-yl)metyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-((4-(1-metylpiperidin-4-yl)piperazin-1-yl)metyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-metansulfonylmetyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-metansulfonyl-etyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-(4-(1-metyl-piperidin-4-yl)piperazin-1-ylmetyl)fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(1-metylpiperidin-4-yl)piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-sykloheksyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(5-(4-etylpiperazin-1-yl)pyridin-2-ylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(5-(4-(2-hydroksy-etyl)-piperazin-1-yl)-piridin-2-ylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; N-(3-(2-(4-(1-(4-etylpiperazin-1-yl)etyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-etylpiperazin-1-karbonyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-(2-hydroksy-acetyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-(2-dimetylamino-acetyl)-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;2-(4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)fenyl)eddiksyre;N-(3-((2-((4-(metylsulfinyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid; N-(3-((2-((4-(metylsulfonyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-N-metylbenzamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-N,N-dimetylbenzamid; N-(3-((2-((4-(morfolin-4-karbonyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(4-metylpiperazin-1-karbonyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-(4-(1-metyl-piperidin-4-yl)-piperazin-1-karbonyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(4-hydroksy-piperidin-1-karbonyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(3-metylamino-pyrrolidin-1-karbonyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(3-dimetylamino-pyrrolidin-1-karbonyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-d]pyrimidin-2-ylamino)-N-(2-dimetylaminoetyl)-benzamid;N-(3-(2-(3-klor-4-(4-etylpiperazin-1-karbonyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-((2-((3-klor-4-((2-(dimetylamino)etyl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-d]pyrimidin-2-ylamino)-2-klor-N,N-dimetylbenzamid;N-(3-(2-(3-klor-4-(4-etansulfonyl-piperazin-1-karbonyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino-2-klor-N-(1-metylpiperidin-4-yl)benzamid; N-(3-(2-(4-(4-etylpiperazin-1-ylsulfonyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-((2-((4-((metylsulfinyl)metyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(2-(metylsulfinyl)etyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-sulfamoylfenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid; N-(3-((2-((4-(morfolinosulfonyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(N-syklopropylsulfamoyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(N-(2-(dimetylamino)etyl)sulfamoyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(N-(1-metylpiperidin-4-yl)sulfamoyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(N-(1-isopropylpiperidin-4-yl)sulfamoyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;3-(dimetylamino)propyl-4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)benzoat;N-(3-(2-(4-(2-(4-etylpiperazin-1-yl)etyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(2-piperidin-1-yl-etyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1,1-diokso-1λ6-tiomorfolin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-(4-etylpiperazin-1-yl)acetyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(1-etylpiperidin-4-yloksy)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yloksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-morfolinoetoksy)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(2-metoksy-etoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-((2-((4-(2-(dimetylamino)etoksy)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid; N-(3-((2-((4-(2-(dietylamino)etoksy)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-(2-(pyrrolidin-1-yl)etoksy)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((2,3,4,5-tetrahydrobenzo[b][1,4]oksazepin-7-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(2,3-dihydro-benzo[1,4]dioksin-6-ylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(2-metoksy-etoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-dimetylamino-etoksy)-3-fluor-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(2-dietylamino-etoksy)-3-fluor-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(2-(4-metyl-piperazin-1-yl)-etoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-metoksy-4-(2-morfolin-4-yl-etoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;(E)-4-(dimetylamino)-N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)but-2-enamid;N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-ylamino)fenyl)akrylamid;N-(3-(2-(4-(4-etyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(4-isopropyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-dimetylaminometyl-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-piperidin-1-ylmetyl-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(2-dimetylamino-etyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-((2-((4-(2-(4-metylpiperazin-1-yl)etyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)amino)fenyl)akrylamid; N-(3-(2-(4-(2-dimetylamino-etoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(3-dimetylamino-propoksy)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-ylamino)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(2-metoksy-4-piperidin-1-ylmetyl-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(4-fluor-3-(2-(4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(4-fluor-3-(2-(3-fluor-4-(4-metyl-piperazin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylamino)-fenyl)-akrylamid;N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yltio)fenyl)akrylamid;N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-ylsulfanyl)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-morfolin-4-yl-fenylamino)-tieno[3,2-d]pyrimidin-4-ylsulfanyl)-fenyl)-akrylamid;(E)-4-(dimetylamino)-N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yltio)fenyl)but-2-enamid;N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-ylsulfinyl)fenyl)akrylamid;(Z)-3-klor-N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;(E)-3-klor-N-(3-(2-(4-(4-metylpiperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-etylpiperazin-1-yl)-2-metoksyfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(2-metoksy-4-morfolinofenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-2-metoksy-N-(1-metylpiperidin-4-yl)benzamid;N-(3-(2-(4-(piperidin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(4-(pyrrolidin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; 1-(4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)fenyl)piperidin-4-karboksylsyre;N-(3-(2-(4-(4-dimetylaminometyl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-1-ylmetyl-piperidin-1-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1-metyl-1,2,3,6-tetrahydro-piridin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1-etyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1-isopropyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-dimetylaminometyl-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-klor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;4-(4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-ylamino)-N(2-(pyrrolidin-1 -yl)etyl)benzamid;N-(3-((2-((4-(2-((1-metylpiperidin-4-yl)amino)-2-oksoetyl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-(3-piperidin-1-yl-propenyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(4-(3-pyrrolidin-1-yl-propionylamino)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino-N-(tetrahydro-2H-pyran-4-yl)benzamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino-N-(1-metylpiperidin-4-yl)benzamid;4-((4-(3-akrylamidofenoksy)tieno[3,2-d]pyrimidin-2-yl)amino)-N-(1-isopropylpiperidin-4-yl)benzamid;4-(4-(3-akryloylamino-fenoksy)-tieno[3,2-d]pyrimidin-2-ylamino)-3-metoksy-N-(2-pyrrolidin-1-yl-etyl)-benzamid;N-(3-(2-(4-(4-(N,N-dimetylsulfamoyl)piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(4-(2-(4-(etylsulfonyl)piperazin-1-yl)etyl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(6-(4-metylpiperazin-1-yl)pyridin-3-ylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-((2-(piridin-3-ylamino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-morfolinopiridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(4-(1-metylpiperidin-4-yl)piperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(4-(2-(dimetylamino)etyl)piperazin-1-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(4-(dimetylamino)piperidin-1-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(4-(pyrrolidin-1-yl)piperidin-1-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-([1,4'-bipiperidin]-1'-yl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-((4-metylpiperazin-1-yl)metyl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-((2-(piperidin-1-yl)etyl)amino)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-((1-isopropylpiperidin-4-yl)amino)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((6-(metylsulfinyl)pyridin-3-yl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(3-fluor-4-morfolinofenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-((2-((3-fluor-4-((1-metylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((3-fluor-4-((1-isopropylpiperidin-4-yl)amino)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(3-fluor-4-(4-(metylsulfonyl)piperazin-1-yl)fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid;N-(3-(2-(4-(4-(etansulfonylpiperazin-1-yl)-3-fluor-fenylamino)tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)akrylamid;N-(3-(2-(4-(2,6-cis-dimetylmorfolino)-3-fluorfenylamino)tieno[3,2-d]pyrimidin-4-yloksy)fenyl)akrylamid; N-(3-(2-(3-fluor-4-(1-metyl-piperidin-4-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(1-metyl-piperidin-3-yl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-(3-fluor-4-(2-morfolin-4-yl-etoksy)fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-((2-((4-((2-(dimetylamino)etyl)amino)-3-fluorfenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((3,5-difluor-4-(4-metylpiperazin-1-yl)fenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((4-((2-(dimetylamino)etyl)amino)-3,5-difluorfenyl)amino)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-((2-((3,5-difluor-4-((1-metylpiperidin-4-yl)amino)fenyl)tieno[3,2-d]pyrimidin-4-yl)oksy)fenyl)akrylamid;N-(3-(2-(4-(1-amino-syklopropyl)-fenylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid;N-(3-(2-[1-(2-dimetylamino-acetyl)-2,3-dihydro-1H-indol-5-ylamino]-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid; ogN-(3-(2-(1-metyl-1H-indol-5-ylamino)-tieno[3,2-d]pyrimidin-4-yloksy)-fenyl)-akrylamid.4. Anvendelse av forbindelsen ifølge krav 1 for fremstilling av et medikament for å forhindre eller behandle kreftformer, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer.5. Anvendelsen ifølge krav 4, hvori kreftene eller svulstene induseres av en epidermal vekstfaktorreseptor (EGFR) tyrosinkinase eller en mutant derav.6. Anvendelsen ifølge krav 4, hvori kreftene, svulstene, de inflammatoriske sykdommene, de autoimmune sykdommene eller immunologisk medierte sykdommene medieres av minst en kinase valgt fra gruppen som består av Brutons tyrosinkinase (BTK), janus kinase 3 (JAK3) , interleukin-2-induserende T-cellekinase (ITK), hvilende lymfocyttkinase (RLK) og benmargtyrosinkinase (BMX).7. Anvendelsen ifølge krav 4, hvori kreftene, svulstene, de inflammatoriske sykdommene, de autoimmune sykdommene eller immunologisk medierte sykdommene medieres av abnomalt aktiverte B-lymfocytter, T-lymfocytter eller begge deler. 8. Anvendelsen ifølge krav 4, hvori de inflammatoriske sykdommene, de autoimmune sykdommene eller de immunologisk medierte sykdommene er leddgikt, revmatoid artritt, spondyloartropati, giktartritt, slitasjegikt, juvenil artritt, annen artrittisk tilstand, lupus, systemisk lupus erytematose (SLE), hudrelatert sykdom, psoriasis, eksem, dermatitt, atopisk dermatitt, smerte, pulmonær lidelse, lungebetennelse, voksen respiratorisk distress-syndrom (ARDS), pulmonal sarkoidose, kronisk pulmonar inflammasjonssykdom, kronisk obstruktiv lungesykdom (KOLS), kardiovaskulær sykdom, arteriosklerose, hjerteinfarkt, kongestiv hjertesvikt, hjertereperfusjonsskade, inflammatorisk tarmsykdom, Crohns sykdom, ulcerøs kolitt, irritabelt tarmsyndrom, astma, Sjøgrens syndrom, autoimmunitetstyroidsykdom, urticaria (cnidosie), multippel sklerose, skleroderma, organtransplantasjonsavstøtning, heteroplastisk transplantat, idiopatisk trombocytopenisk purpura (ITP), Parkinsons sykdom, Alzheimers sykdom, diabetesforbundet sykdom, betennelse, bekkenbetennelsessykdom, allergisk rhinitt, allergisk bronkitt, allergisk bihulebetennelse, leukemi, lymfom, B-cellelymfom,T-cellelymfom, myelom, akutt lymfoid leukemi (ALL), kronisk lymfoid leukemi (CLL), akutt myeloid leukemi (AML), kronisk myeloid leukemi (CML), hårcelleleukemi, Hodgkins sykdom, ikke-Hodgkins lymfom, multippel myelom, myelodysplastisk syndrom (MDS), myeloproliferative neoplasmer (MPN), diffus stor-B-cellelymfom eller follikulært lymfom.9. Anvendelsen ifølge krav 4, som administreres i kombinasjon med et anti-kreftmiddel valgt fra gruppen som består av: cellesignaltransduksjonsinhibitorer, mitoseinhibitorer, alkyleringsmidler, anti-metabolitter, interkalerende anti-kreftmidler, topoisomeraseinhibitorer, immunoterapiske midler, antihormonale midler og en blanding derav.10. Anvendelsen ifølge krav 4, som administreres i kombinasjon med et terapeutisk middel valgt fra gruppen som består av: steroidlegemidler, metotreksater, leflunomider, anti-TNFα-midler, kalsinurininhibitorer, antihistaminlegemidler, og en blanding derav.11. Farmasøytisk sammensetning for anvendelse i en fremgangsmåte for forebygging eller behandling av kreft, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer som omfatter forbindelsen med formel (I) eller dets farmasøytisk akseptable salt ifølge krav 1 som en aktiv bestanddel.12. Forbindelse ifølge et hvilket som helst av kravene 1 til 3 for anvendelse ved behandling. 13. Forbindelse ifølge et hvilket som helst av kravene 1 til 3 for anvendelse i en fremgangsmåte for forebygging eller behandling av kreftformer, svulster, inflammatoriske sykdommer, autoimmune sykdommer eller immunologisk medierte sykdommer.14. Forbindelsen for anvendelse ifølge krav 13, hvori sykdommen er som definert i et hvilket som helst av kravene 5 til 8.15. Forbindelsen ifølge krav 1, hvori forbindelsen ereller et farmasøytisk akseptabelt salt derav.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Hanmi Science Co., Ltd.
550, Dongtangiheung-ro Dongtan-myeon Hwaseong-si, Gyeonggi-do 445-813 KR

Oppfinner(e) info chevron_right

CHA, Mi Young
Hanlla Apt. 306-1102, Cheongsolmaeul,Geumgok-dong,Bundang-gu,Seongnam-si 463-725 Gyeonggi-do KR
KANG, Seok Jong
174-1, Jamo-ri,Gunbuk-myeon,Okcheon-gun, 373-853 Chungcheong-buk-do KR
KIM, Mi Ra
102-ho, 7-31, Yangjae-dong,Seocho-gu 137-130 Seoul KR
LEE, Ju Yeon
Hoban 2-cha Apt. 215-202,Wolgae-dong,Gwangsan-gu, 506-773 Gwangju KR
JEON, Ji Young
Mokryeon Apt. 1213-202,Sanbon-dong,Gunpo-si, 435-040 Gyeonggi-do KR
JO, Myoung Gi
Seongwon 2-cha 202-1106,Anyang-4-dong,Manan-gu,Anyang-si, 430-014 Gyeonggi-do KR
KWAK, Eun Joo
303-4, Seogwi-dong,Seogwipo-si, 679-010 Jeju-do KR
LEE, Kwang Ok
LG Xi Apt. 912-401,Sanghyeon-2-dong,Suji-gu,Yongin-si, 448-132 Gyeonggi-do KR
HA, Tae Hee
Seohae Grable 413-2101,Solbitmaeul,Bansong-dong,Hwaseong-si, 445-758 Gyeonggi-do KR
SUH, Kwee Hyun
225-502, 24, Dongsuwon-ro 145beon-gil,Gwonseon-gu,Suwon-si Gyeonggi-do 16663 KR
KIM, Maeng Sup
Dunchon Jugong Apt. 301-203,Dunchon-dong,Gangdong-gu, 134-060 Seoul KR

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V7156NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
Brevalex
95, rue d'Amsterdam 75378 Paris Cedex 8 FR

Prioritet info chevron_right

2010.06.23, KR 20100059686

Anførte dokumenter info chevron_right

WO-A1-2009/062258 (B1)

WO-A2-2010/054285 (B1)

WO-A1-2009/158571 (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
Patent opphørt Ikke betalt årsavgift
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
14-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
13-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
12-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Opphørt for ikke betalt årsavgift (3206)
11-01 Via Altinn-sending EP Opphørt for ikke betalt årsavgift (3206)
Utgående EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2975042)
10-01 Via Altinn-sending EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2975042)
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
05-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
04-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP2975042)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP2975042)
Innkommende, AR297754109 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 EP oversettelse EP krav
01-03 Fullmakt Fullmakt
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 9. avg. år (EP) 2019.04.05 2850 WIRO LIMITED Betalt og godkjent
31900493 expand_more 2019.02.07 5500 TANDBERG INNOVATION AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 26.04.2025 04:44:19